Overview

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Amikacin
Aminosalicylic Acid
Atazanavir Sulfate
Bedaquiline
Capreomycin
Clofazimine
Cobicistat
Contraceptive Agents
Contraceptives, Oral
Cycloserine
Darunavir
Desogestrel
Dolutegravir
Efavirenz
Elvitegravir
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethambutol
Ethinyl Estradiol
Ethionamide
Etonogestrel
Etravirine
Isoniazid
Kanamycin
Levofloxacin
Linezolid
Lopinavir
Moxifloxacin
Nevirapine
Norgestimate, ethinyl estradiol drug combination
Ofloxacin
Polyestradiol phosphate
Prothionamide
Pyrazinamide
Rifampin
Ritonavir
Tenofovir